Evidence map›Paper›PMID 15793132›Full record

ArticleAntimicrobial agents and chemotherapy2005

Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.

Jyri K Koort, Tatu J Mäkinen, Esa Suokas, Minna Veiranto, Jari Jalava, Juhani Knuuti, Pertti Törmälä, Hannu T Aro

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00841152 (A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00841152 completednot on this mapstarted 2009, after this paper: background citation

A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects

TypeobservationalSponsorTurku University HospitalRan2009 to 2018Enrolled120ConditionsBone NeoplasmArmsBioactive glass, Beta-tricalcium phosphate (ChronOs), Autograft, Allograft (frozen femoral head)
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Flourishing Antibacterial Strategies for Osteomyelitis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Polymer-controlled release of tobramycin from bone graft void filler.Drug delivery and translational research · 2013
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Jyri K KoortOrthopaedic Research Unit, Department of Orthopaedic Surgery and Traumatology, University of Turku, FIN-20520 Turku, Finland.
Tatu J Mäkinen
Esa Suokas
Minna Veiranto
Jari Jalava
Juhani Knuuti
Pertti Törmälä
Hannu T Aro
Orthopaedic Research · GBTampere University · FIPublic Health Institute · USTurku PET Centre · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concept of local antibiotic delivery via biodegradable bone defect fillers with multifunctional properties for the treatment of bone infections is highly appealing. Fillers can be used to obliterate surgical dead space and to provide targeted local bactericidal concentrations in tissue for extended periods. Eventually, the osteoconductive component of the filler could guide the healing of the bone defect. The present experimental study was carried out to test this concept in a localized Staphylococcus aureus osteomyelitis model in the rabbit (n = 31). A metaphyseal defect of the tibia was filled with a block of bone cement, followed by insertion of a bacterial inoculum. After removal of the bone cement and surgical debridement at 2 weeks, the defect was filled with a ciprofloxacin-containing (7.6% +/- 0.1%, by weight) composite (treated-infection group) or with a composite without antibiotic (sham-treated group). Both a positive control group (untreated-infection group) and a negative control group were also produced. The treatment response, monitored by positron emission tomography (PET) with fluorine-18-labeled fluorodeoxyglucose ([18F]FDG) at 3 and 6 weeks, showed rapidly decreasing amounts of [18F]FDG uptake in the treated-infection group (P = 0.001 compared with the results for the untreated-infection group at 6 weeks). The bacteriological analysis confirmed the eradication of the bone pathogen in the treated-infection group. However, three animals had culture-positive soft tissue infections. All animals in the sham-treated and untreated-infection groups had culture-positive bone infections with typical radiographic changes of osteomyelitis. Histomorphometry, peripheral quantitative computed tomography, and backscattered electron imaging of scanning electron microscopy images verified the osteoconductive properties of the bioactive glass microspheres within the composite. The median bone ciprofloxacin concentrations were 1.2 and 2.1 microg/g at two anatomic locations of the tibia. This is the first report to show the value of [18F]FDG PET for quantitative monitoring of the treatment response in bone infections. The collaborative results of bacteriologic and [18F-FDG] PET studies showed that use of the multifunctional composite was successful for eradication of the S. aureus pathogen from bone.

Indexed as

MicrospheresAnimalsAnti-Bacterial AgentsBone CementsCiprofloxacinCoated Materials, BiocompatibleDisease Models, AnimalFluorodeoxyglucose F18GlassHumansLactic AcidMaleOsteomyelitisPolyestersPolymersRabbitsAnti-Bacterial AgentsBone CementsCiprofloxacinCoated Materials, BiocompatibleFluorodeoxyglucose F18Lactic AcidPolyesterspoly(lactide)PolymersRadiopharmaceuticals

Identifiers

PMID15793132
PMCPMC1068592
OpenAlexW2169302651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.